Data from the Syn-Sleep Study shows the Syn-One Test detected phosphorylated alpha-synuclein in skin biopsies of 75% of patients with iRBD at baseline
This NIH-sponsored, multicenter, prospective study is being conducted at 11 sites across the U.S. and involves 80 participants
Dean Rick Schnellmann, PhD, shared with Provost Prelock and President Garimella his decision to step down, effective June 30, 2025. He will return to his tenured faculty position in the Department of Pharmacology and Toxicology after a one-year research leave before resuming research in July 2026.Continue reading
Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine
“Derek’s vision and unwavering commitment to improving patient care have been the driving force behind Castle Biosciences’ remarkable success story,”Continue reading
Imagine the IMPACT of a Biodesign program at the intersection of the #1 most innovative university (Arizona State University) and the #1 hospital in the world (Mayo Clinic)…Continue reading
Up to $142M in funding announced for research group that includes MIT and StanfordContinue reading
Linda Ann St. Pierre Hunt passed away very peacefully on May 17, 2025 at Sherman Home, Hospice of the Valley in Phoenix with her brother Raymond St. Pierre by her side. Linda courageously battled cancer for the past few years as well as other health-related challenges.Continue reading
TUCSON, AZ – UGenome AI, a pioneer in genomic technology, today announced an expanded partnership with Jura Health, Inc. to integrate both pharmacogenomic and nutrigenomic insights into the diagnosis of rare diseases and the development of personalized care plans. By combining expertise in whole genome sequencing (WGS), drug-gene interactions, and nutrient- gene relationships, the collaboration is designed to help rare disease patients receive earlier diagnoses, safer treatments, and lifestyle guidance tailored to their DNA.Continue reading
The U.S. Food and Drug Administration is conducting a national listening tour to meet directly with pharmaceutical and biotech CEOs. Held in major innovation hubs across the country, the CEO Forums will be led by FDA Commissioner Marty A. Makary, M.D., M.P.H., along with Principal Deputy Commissioner Sara Brenner, M.D., M.P.H and Director of FDA’s Center for Biologics Evaluation and Research, Vinay Prasad, M.D., M.P.H.Continue reading
The preclinical stage company was founded to commercialize drugs to treat multiple cancers.Continue reading